BenzingaSeptember 15, 2026 at 6:16 AM NYLast Month
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
